# Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

> **NCT01188668** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Pharmacokinetics
- Cytochrome P-450 CYP2D6
- CYP3A4 Protein, Human

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Aripiprazole + desvenlafaxine succinate sustained release

## Key facts

- **NCT ID:** NCT01188668
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188668, "Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01188668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*